Alzheimer's disease features amyloid-beta plaques and tau tangles, driving neuronal loss and cognitive decline.
Stem cell therapy for Alzheimer's Disease is an investigational regenerative approach that uses living cells — such as mesenchymal stem cells and exosomes — to target the disease process. MSC and exosome protocols target neuro-inflammation and synaptic support in early-stage cognitive decline, as an adjunct to standard care. It is not an approved cure for Alzheimer's Disease: results come from early-phase clinical trials and clinic case series, not large randomised studies, and the realistic goal is slowed progression or symptom improvement rather than reversal.
New to Alzheimer's Disease? Read our plain-English guide to the 7 stages of Alzheimer's Disease.
Alzheimer's disease features amyloid-beta plaques and tau tangles, driving neuronal loss and cognitive decline. Stem-cell approaches address several pathways: placental mesenchymal stem cells are studied for neuroprotection — secreting anti-inflammatory and growth factors that may slow neuronal death — while exosomes derived from stem cells are explored as carriers for therapeutic molecules across the blood-brain barrier and as modulators of amyloid and tau biology. The rationale builds on evidence that stem-cell products reduce neuroinflammation and may support hippocampal neuroplasticity. Reversing established pathology and achieving adequate brain delivery remain unsolved; early trials are small and heterogeneous, with uncertain durability.
| Cost indicativ · Bulgaria (UE) | €3,000–€8,000 |
|---|---|
| Gama costurilor pieței globale | €18,900–€21,000 (bookinghealth.com) |
| Principalele tipuri de celule studiate | MSCs from Amniotic Membrane, Exosomes |
| Statutul aprobării | Investigațional |
| Studii înregistrate (ClinicalTrials.gov) | 41 · 9 recruiting now |
For the clinic's own description, see how Stem Plus describes its Alzheimer's Disease programme ↗.
Forty-one registered trials and 9 recruiting studies investigate stem-cell therapy in Alzheimer's. Small cohorts describe modest cognitive-score changes over 6–12 months; most are uncontrolled. Some show shifts in cerebrospinal-fluid or PET amyloid/tau markers, with less consistent functional gains. No trial has prevented decline or shown reversal of neuronal loss. Approved amyloid-targeting antibodies (lecanemab, aducanumab) show modest slowing of early decline — stem-cell benefit is not proven to match them.
Depending on assessment, a Alzheimer's Disease protocol may draw on:
Indicative European costs are roughly €3,500–€7,000 per course; exosome-based protocols can reach €5,000–€8,000 due to manufacturing complexity. Pre/post neuroimaging (MRI, PET) adds further expense, and multi-dose protocols are common. For context, approved Alzheimer's drugs range from inexpensive symptomatic agents to costly antibody infusions — the stem-cell figure is indicative and less evidence-backed.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Alzheimer's Disease cost-by-country breakdown, or compare the best countries for Alzheimer's Disease →
Before booking, check safety & regulation, the recovery climate, dacă ai putea fi candidat, and which cell type fits Alzheimer's Disease.
FAQ complet Boala Alzheimer → · Defalcare costuri Boala Alzheimer →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Sunt eu un candidat? · Ce tip de celulă? · Types of clinics & best countries · Calculator de costuri
Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Last reviewed 2026-07-23; see our editorial standards. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită